AHPA Reports

AHPA's monthly newsletter. Members log in to access issues of the AHPA Report.

FDA warning letters dive into detail in the January 2018 AHPA Report!

January 2018 AHPA Report

Published: Thursday, January 11, 2018

In this issue of AHPA Report:

Special topic:

FDA warning letters dive into detail by Anthony Young, Esq., Kleinfeld, Kaplan & Becker LLP and AHPA General Counsel

Plus:

AHPA submits comments on pre-DSHEA dietary ingredients list
AHPA participates in CIR panel discussion on 4 herbal ingredients
Industry coalition: Dietary supplements cannot claim to treat opioid addiction
AHPA mourns the passing of Jim Duke
...and much more!

2022 Annual Fund Sponsors

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.


	Address: 8630 Fenton Street, Suite 918, Silver Spring, MD 20910 Phone: 301.588.1171 Email: ahpa@ahpa.org ©Copyright 2022 AHPA

AHPA Reports

AHPA Reports

FDA warning letters dive into detail in the January 2018 AHPA Report!

January 2018 AHPA Report

In this issue of AHPA Report:

Special topic:

FDA warning letters dive into detail by Anthony Young, Esq., Kleinfeld, Kaplan & Becker LLP and AHPA General Counsel

Plus:

AHPA submits comments on pre-DSHEA dietary ingredients list

AHPA participates in CIR panel discussion on 4 herbal ingredients

Industry coalition: Dietary supplements cannot claim to treat opioid addiction

AHPA mourns the passing of Jim Duke ...and much more!

AHPA mourns the passing of Jim Duke
...and much more!